Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation

MILAN, Oct. 15, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, unveiled its Hyatrue® Sterile Sodium Hyaluronate (HA) and showcased its BloomseaN™ Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) at CPHI Milan. Known to be at "the...

2024-10-15 21:00 748

Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. * PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney...

2024-10-15 09:51 1208

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

VEVEY, Switzerland, Oct. 14, 2024 /PRNewswire/ -- Recently at Nestlé's headquarters inVevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its "Human Milk Oligosaccharides (HMO) Research Traceability Journey". With a focus on the most rece...

2024-10-14 23:31 1091

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

Highlights * United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY. * The positive results of the completed COBRA and PROPELLER trials,...

2024-10-14 21:02 1742

Tsingke Shines at Cell & Gene Therapy International 2024

BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...

2024-10-14 20:11 1417

Tsingke Shines at Cell & Gene Therapy International 2024

US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute

TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...

2024-10-14 19:00 1629

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...

2024-10-14 19:00 1549

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina, which recently expanded into the U.S. market following its U.S. FDA 510(k) clea...

2024-10-14 17:00 916

BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)

SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place fromOctober 23 to 27 in San Di...

2024-10-14 15:38 1479

21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain

TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled forSaturday, October 19, 2024, at the Hyatt Regency Hotel inSanta Clara, California, will focus on the theme "Taiwan's Strategic Layout in the AI Era." The conference will explore howTaiwan leverages its...

2024-10-14 10:32 1201

21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain

Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX

HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Zhejiang Taimei Medical Technology Co., Ltd. (the "Company"; Stock code: 2576.HK) has announced that the shares have started to be traded on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code "2576" since today. The Company sai...

2024-10-14 10:18 1192

Modern Meadow Appoints David Williamson as CEO

With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...

2024-10-14 09:00 1028

Modern Meadow Appoints David Williamson as CEO

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...

2024-10-13 20:27 3352

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...

2024-10-13 16:04 2034

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...

2024-10-12 16:57 4021

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

X3 Holdings Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Requirement

SINGAPORE, Oct. 11, 2024 /PRNewswire/ -- X3 Holdings Co., Ltd. (Nasdaq: XTKG) (the "Company" or "XTKG"), a global provider of digital solutions and technology services spanning diverse industries, today announced that it has received an extension of 180 calendar days from the Listing Qualificatio...

2024-10-12 04:30 5292

Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024

Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...

2024-10-11 20:00 4384

GenScript Biotech Advances Sustainable Development with MSCI ESG Rating Upgrade to A

PISCATAWAY, N.J., Oct. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation has recently been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally recognized rating agency. This upgrade reflects GenScript's unwavering commitment to integrating su...

2024-10-11 17:09 2341

Waterdrop Inc. Released 2023 ESG Report: Adhere to both Sci-tech Innovation and Social Responsibility

BEIJING, Oct. 11, 2024 /PRNewswire/ -- Waterdrop Inc. released its Environmental, Social and Governance (ESG) Report 2023 ("the Report") in October. The Report details Waterdrop Inc.'s efforts in a number of key areas such as corporate governance, technology and innovation, inclusive protection ...

2024-10-11 12:44 1607

Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province

BEIJING, Oct. 10, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...

2024-10-11 00:53 1999

Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province

1 ... 7 8 91011 12 13 ... 277